#1 Clinical Trials Search in Europe

C1 Esterase Inhibitor (Human)

C1 Esterase Inhibitor (Human) is a medication being studied in clinical trials for its potential benefits in treating hereditary angioedema (HAE) attacks and traumatic brain injury (TBI). These trials aim to evaluate the safety and effectiveness of this drug in managing these conditions, which can have significant impacts on patients’ lives. The studies involve different formulations and dosing regimens of C1 Esterase Inhibitor (Human) to address specific medical needs.

Table of Contents

What is C1 Esterase Inhibitor (Human)?

C1 Esterase Inhibitor (Human), also known as C1-INH, is a protein derived from human blood plasma. It’s a medication used to treat and prevent a specific type of swelling disorder.[1] This protein plays a crucial role in regulating various bodily processes, particularly those related to inflammation and swelling.

Medical Conditions Treated

The primary condition treated with C1 Esterase Inhibitor (Human) is Hereditary Angioedema (HAE). HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the hands, feet, face, and airways.[1]

There are different types of HAE:

  • HAE Type I: The most common form, where the body doesn’t produce enough C1 inhibitor.
  • HAE Type II: The body produces C1 inhibitor, but it doesn’t function correctly.

Both types are caused by a deficiency in the C1 esterase inhibitor, which this medication aims to address.[1]

How C1 Esterase Inhibitor Works

C1 Esterase Inhibitor (Human) works by replacing the missing or malfunctioning C1 inhibitor in patients with HAE. This helps to:

  • Regulate the complement system (a part of the immune system)
  • Control inflammation
  • Prevent excessive swelling
By providing the body with functional C1 inhibitor, the medication helps to manage and prevent HAE attacks.[1]

Administration and Dosage

C1 Esterase Inhibitor (Human) is typically administered through intravenous injection (directly into a vein). The dosage is usually calculated based on the patient’s body weight. For example, one study used a dose of 20 International Units (IU) per kilogram of body weight.[1]

The medication can be used in two main ways:

  1. Treatment of acute attacks: Given when an HAE attack occurs to reduce symptoms and shorten the duration of the attack.
  2. Pre-procedure prevention: Administered before medical, dental, or surgical procedures to prevent HAE attacks that might be triggered by these interventions.[1]

Efficacy and Benefits

Clinical trials have shown promising results for C1 Esterase Inhibitor (Human) in treating HAE:

  • It can provide relief from HAE symptoms within 4 hours of administration for many patients.
  • The medication is effective in treating attacks affecting various body parts, including potentially life-threatening laryngeal (throat) attacks.
  • It can be used effectively for repeated attacks.
  • When used preventively before medical procedures, it can reduce the occurrence of HAE attacks.[1]

Safety and Side Effects

While C1 Esterase Inhibitor (Human) is generally considered safe, like all medications, it can have side effects. Some potential side effects and safety considerations include:

  • Injection site reactions
  • Hypersensitivity or allergic reactions
  • Potential risk of blood-borne infections (as it’s derived from human blood)
  • Possible risk of blood clots (thromboembolic events) in some patients
It’s important to discuss any concerns or potential risks with your healthcare provider.[1]

Ongoing Research

Research on C1 Esterase Inhibitor (Human) is ongoing, not only for HAE but also for other conditions. For example, a study is investigating its potential use in patients with traumatic brain injury. This research aims to explore whether the anti-inflammatory properties of C1 inhibitor could help reduce brain swelling and improve outcomes in these patients.[2]

This ongoing research highlights the potential for C1 Esterase Inhibitor (Human) to have broader applications beyond HAE, particularly in conditions where inflammation plays a significant role.

Aspect Hereditary Angioedema (HAE) Trial Traumatic Brain Injury (TBI) Trial
Study Phase Phase 3 Not specified
Main Objective Confirm superiority of OCTA-C1-INH over placebo for HAE attack relief Study safety and efficacy of C1-INH in TBI patients
Primary Endpoint Time to beginning of unequivocal symptom relief Therapy Intensity Level Scale
Key Secondary Endpoints Percentage of responders, changes in symptom severity, quality of life Serious Adverse Events, Glasgow Outcome Scale Extended
Age of Participants ≥2 years old Not specified
Administration Route Intravenous injection Intravenous use
Dosage 20 IU/kg body weight Up to 6000 IU daily
Treatment Duration Multiple attacks over study period Up to 1 day

FAQ

  • What is C1 Esterase Inhibitor (Human) being studied for? C1 Esterase Inhibitor (Human) is being studied for treating and preventing acute hereditary angioedema (HAE) attacks and for managing traumatic brain injury (TBI).
  • How is C1 Esterase Inhibitor (Human) administered in these trials? In the trials, C1 Esterase Inhibitor (Human) is administered through intravenous (IV) injection. The dosage and frequency may vary depending on the specific study and condition being treated.
  • Who can participate in these clinical trials? Eligibility varies by study. For the HAE trial, participants must be at least 2 years old with confirmed HAE type I or II. For the TBI study, patients with traumatic brain injury are eligible. Specific inclusion and exclusion criteria apply for each trial.
  • What are the main goals of these clinical trials? The main goals are to assess the safety and efficacy of C1 Esterase Inhibitor (Human) in treating HAE attacks and TBI. This includes evaluating symptom relief, quality of life improvements, and monitoring for any adverse effects.
  • How long do these clinical trials last? The duration varies by study. The HAE trial includes multiple periods such as screening, treatment, and follow-up, which may last several months. The TBI study duration is not specified in the provided information but typically involves acute treatment and follow-up assessments.

Ongoing Clinical Trials on C1 Esterase Inhibitor (Human)

  • Study on the Safety and Effectiveness of C1 Esterase Inhibitor and Sodium Chloride for Patients with Aneurysmal Subarachnoid Hemorrhage

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on C1 Esterase Inhibitor for Treating and Preventing Hereditary Angioedema Attacks in Patients with C1-INH Deficiency

    Recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Romania

  • Study on the Safety and Effectiveness of C1 Esterase Inhibitor and Sodium Chloride for Patients with Traumatic Brain Injury

    Recruiting

    2 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Hereditary Angioedema (HAE): A rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the limbs, face, intestinal tract, and airways.
  • C1 Esterase Inhibitor (C1-INH): A protein in the blood that helps regulate several complex processes involved in the immune system. In HAE, there is a deficiency or dysfunction of this protein.
  • Traumatic Brain Injury (TBI): A disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury.
  • Intravenous (IV) Injection: A method of administering medication directly into a vein using a needle or tube.
  • Efficacy: The ability of a treatment to produce a desired or intended result.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Visual Analog Scale (VAS): A measurement tool used to help patients rate the intensity of certain sensations and feelings, such as pain.
  • Quality of Life (QoL): A measure of an individual's well-being that includes physical, mental, and social aspects of their life.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Glasgow Outcome Scale Extended: A scale used to assess the outcome and degree of recovery of patients with brain injuries.

References

  1. http://clinicaltrials.eu/trial/study-on-c1-esterase-inhibitor-for-treating-and-preventing-hereditary-angioedema-attacks-in-patients-with-c1-inh-deficiency/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-c1-esterase-inhibitor-and-sodium-chloride-for-patients-with-traumatic-brain-injury/